Catalyst Pharmaceuticals (CPRX) Net Equity Issued and Repurchased (2011 - 2024)

Catalyst Pharmaceuticals' (CPRX) quarterly Net Equity Issued and Repurchased came in at $141.0 million in Q1 2024, up 304.31% on a QoQ basis from $34.9 million in Q1 2015.

Catalyst Pharmaceuticals (CPRX) Net Equity Issued and Repurchased (2011 - 2024) Analysis & Trends

Catalyst Pharmaceuticals (CPRX) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $141.0 million in Q1 2024.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $141.0 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $141.0 million (changed N/A YoY) and the FY2024 annual result came in at $141.0 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased improved to $141.0 million in Q1 2024, from $34.9 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $141.0 million in Q1 2024 to a low of $141.0 million in Q1 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Catalyst Pharmaceuticals 3.85 Bn 3.09 Bn 134.92 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2024 141.00 Mn
Mar 31, 2024 141.00 Mn
Mar 31, 2015 34.87 Mn
Mar 31, 2015 34.87 Mn
Jun 30, 2011 -271,366.00
Jun 30, 2011 -271,366.00